What is the main impact of this amendment on Amgen's financial performance?

The main financial impact for Amgen is the elimination of royalty payments to Novartis on U.S. Aimovig sales and the cessation of sharing U.S. commercialization costs. This is expected to improve Amgen's net revenue and profitability from Aimovig sales within the United States.

How does this change affect the global commercialization of Aimovig?

Globally, Novartis will now exclusively handle commercialization of Aimovig outside the U.S. and Japan. Amgen will continue to share development expenses worldwide, but its direct involvement in commercialization outside of specific territories may be reduced, while Novartis takes on a more focused role in those regions.

What is the significance of terminating the U.S. Collaboration Agreement?

The termination of the U.S. Collaboration Agreement appears to be a procedural step concurrent with the new amendment, formalizing the shift in commercialization responsibilities and cost-sharing arrangements within the United States. It essentially clears the way for the new terms under Amendment No. 3 to take effect.

Does Amgen still have any rights or responsibilities related to Aimovig in the U.S. market?

Yes, Amgen continues to be involved in the U.S. market for Aimovig. While it no longer pays royalties or shares commercialization costs, it benefits from these changes by retaining more revenue from U.S. sales. The exact nature of its ongoing operational involvement in the U.S. is not detailed in this filing but development costs are still shared globally.

AMGN 8-K: Material Agreements

Summary

Amgen Inc. (AMGN) filed an 8-K on January 31, 2022, announcing significant amendments to its Exclusive License and Collaboration Agreement with Novartis concerning the commercialization of Aimovig. Primarily, Novartis will now hold exclusive rights to commercialize Aimovig outside of the United States and Japan. This restructuring eliminates Amgen's royalty obligations to Novartis on U.S. Aimovig sales and also removes the cost-sharing arrangement for U.S. commercialization, simplifying Amgen's operational responsibilities in its home market. While Amgen will no longer pay royalties on U.S. sales and will cease sharing U.S. commercialization costs, the companies will continue to share development expenses globally for Aimovig. This amendment, effective January 31, 2022, also involves the termination of a prior U.S. Collaboration Agreement. These changes indicate a strategic shift in how Aimovig will be marketed and managed in key regions, with Amgen potentially retaining more of the U.S. revenue while offloading certain U.S. commercialization burdens.

Key Highlights

1Novartis gains sole rights to commercialize Aimovig outside the United States and Japan.
2Amgen will no longer pay royalties to Novartis on Aimovig sales within the United States.
3Amgen and Novartis will cease sharing the costs of Aimovig commercialization in the United States.
4Development expenses for Aimovig will continue to be shared worldwide by both parties.
5The amendment was executed on January 31, 2022, and concurrently terminated a prior U.S. Collaboration Agreement.
6This move simplifies Amgen's commercialization responsibilities and financial obligations in the U.S. market for Aimovig.

AMGEN INC 8-K Report, Material Agreement (Jan 31, 2022)

Summary

Key Highlights

Frequently Asked Questions